Welcome to our dedicated page for Cardinal Health SEC filings (Ticker: CAH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cardinal Health, Inc. filings document material events for a healthcare distribution and medical products company, including quarterly results, Regulation FD outlook updates and earnings presentation exhibits. The records tie financial reporting to segment performance, capital returns, debt reduction and corporate finance matters such as revolving credit agreements that support the commercial paper program.
Governance filings cover board composition, annual meeting voting results, director and officer transitions, and related compensation or succession disclosures. The company’s 8-K record also includes material definitive agreements, shareholder voting matters, financial covenants, exhibits and other capital-structure disclosures for Cardinal Health’s public-company profile.
Cardinal Health, Inc. entered into a new 364-day credit agreement on October 7, 2025 with Bank of America, N.A. as administrative agent and a syndicate of lenders. The facility provides access to up to $1.0 billion of revolving credit through October 6, 2026 and replaces a similar 364-day agreement that expired from October 2024.
At the termination date, Cardinal Health may, subject to conditions in the agreement, convert any outstanding borrowings into non-revolving term loans that must be repaid one year later. The agreement includes customary representations, covenants and events of default, including a financial covenant requiring a consolidated net leverage ratio not greater than 3.75 to 1.00 as of the last day of any fiscal quarter.
The revolving credit facility may be used for general corporate purposes and backs the company’s commercial paper program. Participating financial institutions and their affiliates have previously provided, and may continue to provide, various banking and financial services to Cardinal Health for customary fees.
Cardinal Health, Inc. reported that several of its receivables financing subsidiaries and major banking partners entered into a First Amendment to an existing Fifth Amended and Restated Receivables Purchase Agreement originally dated September 1, 2023. The principal change is an extension of the term of this receivables financing facility to September 28, 2028, helping maintain access to funding backed by customer receivables.
Key counterparties include Wells Fargo, Liberty Street Funding, The Bank of Nova Scotia, PNC Bank, Bank of America, Victory Receivables Corporation and MUFG Bank. These institutions or their affiliates also provide other services to Cardinal Health, such as acting as dealers under its commercial paper program and participating in its $2.0 billion revolving credit facility.
Cardinal Health's proxy highlights strong fiscal 2025 operating and governance outcomes. GAAP diluted EPS was $6.45 (prior year included a $617 million after-tax goodwill impairment of $2.50 per share). Non-GAAP diluted EPS was $8.24, a 9% increase year-over-year. The company generated $2.4 billion in operating cash flow, returned over $1.2 billion to shareholders ($750 million in repurchases and $494 million in dividends), invested $547 million in the business, and deployed $5.3 billion on acquisitions including ION, GI Alliance and Advanced Diabetes Supply Group. Performance share units for the 2023–2025 cycle settled at 212% of target after a 20% TSR modifier; three‑year TSR was 235.5% vs. 9.4% for the S&P 500 Health Care Index. Governance disclosures detail an independent, non-executive chairman, recent director additions (Messrs. Musslewhite and Ramakrishna), board refreshment practices, and executive compensation governance, including a disclosed CEO-to-median pay ratio of 261:1.
Cardinal Health's proxy highlights strong fiscal 2025 operating and governance outcomes. GAAP diluted EPS was $6.45 (prior year included a $617 million after-tax goodwill impairment of $2.50 per share). Non-GAAP diluted EPS was $8.24, a 9% increase year-over-year. The company generated $2.4 billion in operating cash flow, returned over $1.2 billion to shareholders ($750 million in repurchases and $494 million in dividends), invested $547 million in the business, and deployed $5.3 billion on acquisitions including ION, GI Alliance and Advanced Diabetes Supply Group. Performance share units for the 2023–2025 cycle settled at 212% of target after a 20% TSR modifier; three‑year TSR was 235.5% vs. 9.4% for the S&P 500 Health Care Index. Governance disclosures detail an independent, non-executive chairman, recent director additions (Messrs. Musslewhite and Ramakrishna), board refreshment practices, and executive compensation governance, including a disclosed CEO-to-median pay ratio of 261:1.
Cardinal Health, Inc. filed an 8-K reporting execution of a Third Supplemental Indenture dated August 27, 2025, with The Bank of New York Mellon Trust Company, N.A., as trustee, and included forms of two note series: 4.500% Notes due 2030 and 5.150% Notes due 2035. The filing incorporates the original Indenture dated June 2, 2008, and includes legal opinions and consents from Cardinal Health's General Counsel and White & Case LLP, plus an embedded Inline XBRL cover page.
The disclosure documents appear to support issuance or amendment of long-term debt instruments by the company and provide legal and trustee documentation required for such securities. The filing is signed by Aaron E. Alt, Chief Financial Officer.
Cardinal Health (CAH) Form 144 notice reports a proposed sale of 21,367 common shares through Merrill Lynch on 08/20/2025 with an aggregate market value of $3,216,330.00. The filing shows the shares were acquired on 08/15/2025 from Cardinal Health, Inc. as 13,088 shares from performance stock vesting and 8,279 shares from restricted stock vesting. No securities were reported sold by the same person in the past three months. The document includes the required representation that the seller is not aware of undisclosed material adverse information and references potential Rule 10b5-1 plan considerations.
Insider sale by Cardinal Health officer: The Form 4 shows Deborah Weitzman, identified as an officer (CEO, PSS Segment), sold 21,367 common shares on 08/20/2025 at a weighted average price of $150.53 per share (sales ranged $150.22 to $151.00). After the reported dispositions she beneficially owned 53,428 shares. The filing notes the weighted-average price and offers to provide detailed per-trade quantities and prices on request. No derivative transactions or additional acquisitions are reported in this Form 4.
Insider transactions reported for Cardinal Health, Inc. (CAH). The Form 4 shows Jason M. Hollar, listed as Chief Executive Officer and an officer reporting person, sold common shares on 08/20/2025 in two separate sets of transactions. The first sale disposed of 12,944 shares at a weighted average price of $149.40, leaving 222,957 shares beneficially owned. The second sale disposed of 22,957 shares at a weighted average price of $150.40, leaving 200,000 shares beneficially owned following that reported transaction.
The filings note the prices are weighted averages from multiple trades within specified ranges and state the reporting person will provide further breakdowns on request. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person.
Mary C. Scherer, Chief Accounting Officer of Cardinal Health, Inc. (CAH), reported multiple transactions on Form 4. She was granted 1,203 restricted stock units (RSUs) on 08/15/2025 that vest in three equal annual installments beginning 08/15/2026. To satisfy tax withholding on vested awards, 2,572 shares were withheld (reported as a disposition at $150.22, reflecting prior close). Separately, 6,766 common shares were sold on 08/19/2025 at a weighted average price of $149.25, with sale prices ranging $148.94–$149.60. After these transactions her reported beneficial ownership of common shares is 3,556 shares.
Cardinal Health insider filings show multiple equity transactions by Michelle D. Greene, the company's Chief Information Officer. On 08/15/2025 Greene received a grant of 3,476 restricted share units (RSUs) that vest in three equal annual installments beginning 08/15/2026. The filing also discloses withholding of 9,968 shares to satisfy taxes related to the vesting of 6,787 RSUs and 16,362 performance share units, using a prior-business-day closing price of $150.22. On 08/19/2025 Greene sold a total of 13,500 common shares in multiple transactions at weighted-average prices of $148.76 and $149.28, reducing beneficial ownership from 38,444 to 14,976 shares.
Mason Stephen M, an officer (CEO, GMPD Segment) of Cardinal Health, Inc. (CAH), reported multiple transactions in the companys common stock on 08/15/2025 and 08/19/2025. On 08/15/2025 he received a grant of 8,957 restricted stock units (RSUs) that vest in three equal annual installments beginning 08/15/2026, increasing his beneficial holdings to 98,471 shares. Also on 08/15/2025, 30,811 shares were withheld to satisfy tax obligations related to vesting, reducing holdings to 67,660 shares. On 08/19/2025 he sold a total of 41,575 shares in multiple transactions at weighted average prices of about $147.87, $148.83, and $149.39, resulting in 26,085 shares beneficially owned after the reported sales. The Form 4 discloses price ranges and notes weighted-average pricing for those sales.